Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial DOI
Jordi Bruix, Tadatoshi Takayama, Vincenzo Mazzaferro

et al.

The Lancet Oncology, Journal Year: 2015, Volume and Issue: 16(13), P. 1344 - 1354

Published: Sept. 8, 2015

Language: Английский

Global burden of primary liver cancer in 2020 and predictions to 2040 DOI Creative Commons
Harriet Rumgay, Melina Arnold, Jacques Ferlay

et al.

Journal of Hepatology, Journal Year: 2022, Volume and Issue: 77(6), P. 1598 - 1606

Published: Oct. 5, 2022

Language: Английский

Citations

1120
Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study DOI Creative Commons
Joong‐Won Park, Minshan Chen,

M. Colombo

et al.

Liver International, Journal Year: 2015, Volume and Issue: 35(9), P. 2155 - 2166

Published: March 5, 2015

Hepatocellular carcinoma (HCC) is the second most common cause of cancer deaths worldwide. The global HCC BRIDGE study was a multiregional, large-scale, longitudinal cohort undertaken to improve understanding real-life management patients with HCC, from diagnosis death.Data were collected retrospectively January 2005 September 2012 by chart reviews eligible newly diagnosed at participating institutions.Forty-two sites in 14 countries contributed final data for 18 031 patients. Asia accounted 67% patients, Europe 20% and North America 13%. As expected, risk factor hepatitis C virus America, Japan, B China, South Korea Taiwan. Barcelona Clinic Liver Cancer stage Europe, China Korea, A Taiwan Japan. Across all stages, first treatment frequently transarterial chemoembolization percutaneous ethanol injection or radiofrequency ablation Japan resection Survival varied significantly region, median overall survival not reached 60, 33, 31, 24 23 months respectively (P < 0.0001).Initial results confirm previously reported regional trends patient demographic characteristics factors, document heterogeneity approaches across regions/countries underscore need earlier

Language: Английский

Citations

1013
Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis DOI Creative Commons
Daniela Sia, Augusto Villanueva, Scott L. Friedman

et al.

Gastroenterology, Journal Year: 2016, Volume and Issue: 152(4), P. 745 - 761

Published: Dec. 30, 2016

Language: Английский

Citations

1009
New trends on obesity and NAFLD in Asia DOI Open Access

Jian-Gao Fan,

Seung Up Kim, Vincent Wai–Sun Wong

et al.

Journal of Hepatology, Journal Year: 2017, Volume and Issue: 67(4), P. 862 - 873

Published: June 20, 2017

Language: Английский

Citations

983
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial DOI
Jordi Bruix, Tadatoshi Takayama, Vincenzo Mazzaferro

et al.

The Lancet Oncology, Journal Year: 2015, Volume and Issue: 16(13), P. 1344 - 1354

Published: Sept. 8, 2015

Language: Английский

Citations

978